MedPath

SUSTOL

These highlights do not include all the information needed to use SUSTOL safely and effectively. See full prescribing information for SUSTOL.SUSTOL (granisetron) extended-release injection, for subcutaneous useInitial U.S. Approval: 1993

Approved
Approval ID

f7c7ffdd-8270-4030-bc1e-a1cb28a6de56

Product Type

HUMAN PRESCRIPTION DRUG LABEL

Effective Date

Jun 7, 2023

Manufacturers
FDA

Heron Therapeutics, Inc.

DUNS: 102099843

Products 1

Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.

granisetron

Product Details

FDA regulatory identification and product classification information

FDA Identifiers
NDC Product Code47426-101
Application NumberNDA022445
Product Classification
M
Marketing Category
C73594
G
Generic Name
granisetron
Product Specifications
Route of AdministrationSUBCUTANEOUS
Effective DateMay 31, 2017
FDA Product Classification

INGREDIENTS (2)

GRANISETRONActive
Quantity: 10 mg in 0.4 mL
Code: WZG3J2MCOL
Classification: ACTIB
METHOXY PEG-10Inactive
Code: UQE3488NAI
Classification: IACT

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

SUSTOL - FDA Drug Approval Details